Online citations, reference lists, and bibliographies.
← Back to Search

Early Detection Of Anthracycline-Induced Cardiotoxicity By Radionuclide Angiocardiography

J. Suzuki, A. Yanagisawa, Toshiki Shigeyama, J. Tsubota, T. Yasumura, K. Shimoyama, K. Ishikawa
Published 1999 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
For the early detection of myocardial damage associated with anthracycline therapy, electrocardiography, echocardiography, and radionuclide angiocardiography were used to assess cardiac function in 37 patients receiving anthracyclines (ie, adriamycin and daunorubicin at a total dose of 100-2,030 mg/m2). None of the patients developed clinical congestive heart failure. There were no significant changes of electrocardio graphic and echocardiographic parameters after anthracycline administration. The left ventricular ejection fraction did not change significantly on radionuclide angiocardiog raphy. However, the 1/3 peak filling rate (PFR) corrected by the end-diastolic count (EDC) (1/3 PFR/EDC) and the 1/3 filling fraction (1/3 FF), the indices of early diastolic function, showed a significant decrease. These findings suggest that the 1/3 PFR/EDC and 1/3 FF determined by radionuclide imaging are useful for detecting silent myocardial damage induced by anthracyclines.
This paper references
Assessment of left ventricular diastolic function: comparison of contrast ventriculography and equilibrium radionuclide angiography.
B. Villari (1991)
10.1002/1097-0142(197402)33:2<545::AID-CNCR2820330233>3.0.CO;2-M
Daunorubicin cardiac toxicity in children with acute lymphocytic leukemia
J. F. Halazun (1974)
10.1016/0305-7372(93)90027-O
Strategies for prevention of anthracycline cardiotoxicity.
R. Basser (1993)
Resting early peak diastolic filling rate: a sensitive index of myocardial dysfunction in patients with coronary artery disease.
J. Polak (1982)
10.1016/S0022-3476(84)80026-8
QT interval prolongation associated with anthracycline cardiotoxicity.
K. S. Bender (1984)
10.1016/0002-9149(90)90939-X
Effects of preload reduction on mitral flow velocity pattern in normal subjects.
M. Triulzi (1990)
10.1016/0002-9343(87)90212-9
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
10.1002/1097-0142(197308)32:2<302::AID-CNCR2820320205>3.0.CO;2-2
A clinicopathologic analysis of adriamycin cardiotoxicity
E. Lefrak (1973)
10.1002/1097-0142(19850701)56:1<76::AID-CNCR2820560113>3.0.CO;2-S
Doxorubicin hydrochloride (adriamycin) cardiotoxicity evaluated by sequential radionuclide angiocardiography
M. Piver (1985)
10.1253/JCJ.58.625
Early detection of anthracycline cardiotoxicity in children with acute leukemia using exercise-based echocardiography and Doppler echocardiography.
R. Fukazawa (1994)
10.1136/hrt.73.4.340
Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology.
F. Bu'lock (1995)
10.1016/S0305-7372(76)80018-7
Cardiotoxicity of adriamycin and related anthracyclines.
L. Lenaz (1976)
Adriamycin (NSC 123127) cardiomyopathy. An overview with determination of risk factors
R. A. Minow (1975)
10.1001/ARCHINTE.1988.00380010103010
Diastolic function of the heart in clinical cardiology.
R. Harizi (1988)
10.1007/BF03288464
DOXORUBICIN CARDIOTOXICITY
D. Unverferth (1982)
10.1002/MPO.2950050123
Echocardiographic assessment of anthracycline cardiotoxicity in children.
A. Lewis (1978)
10.5555/URI:PII:009377549290207H
The cardiotoxicity of chemotherapeutic drugs.
A. Allen (1992)
10.1002/AJH.2830360314
Severe and fatal anthracycline cardiotoxicity at cumulative doses below 400 mg/m2: Evidence for enhanced toxicity with multiagent chemotherapy
R. Watts (1991)
10.1016/0002-9149(91)90798-P
Influence of Doppler sample volume location on ventricular filling velocities.
W. Jaffe (1991)
10.1161/01.CIR.55.4.613
Echocardiographic Determination of Left Ventricular Mass in Man: Anatomic Validation of the Method
R. Devereux (1977)
10.1002/1097-0142(19810615)47:12<2810::AID-CNCR2820471210>3.0.CO;2-4
Congestive heart failure due to adriamycin cardiotoxicity: Its natural history in children
A. Goorin (1981)
10.1200/JCO.1984.2.2.112
A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving Adriamycin.
M. Ewer (1984)
Adriamycin— an antitumor antibiotic in treatment of neoplastic diseases
C Tan (1973)
10.1016/0002-9343(77)90315-1
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.
D. V. Von Hoff (1977)
Radionuclide ventriculography for evaluation and prevention of doxorubicin cardiotoxicity.
Steinberg Js (1985)
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
M. Bristow (1978)
10.1016/0002-8703(89)90077-X
Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics.
B. Marchandise (1989)
10.1056/NEJM198107163050305
The anthracycline antineoplastic drugs.
R. C. Young (1981)
10.1097/00000421-199304000-00005
Detection of Early Anthracycline Cardiotoxicity by Monitoring the Peak Filling Rate
W. Ganz (1993)
10.1097/00004872-198900076-00046
Correlations between M-mode markers of left ventricular hypertrophy and radionuclide angiographic indices of left ventricular diastolic function in mild to moderate hypertension.
P. Granier (1989)
10.1016/S0735-1097(86)80461-2
Noninvasive assessment of left ventricular diastolic function: comparative analysis of Doppler echocardiographic and radionuclide angiographic techniques.
P. Spirito (1986)
Adriamycin cardiotoxicity: a survey of 1273 patients.
C. Praga (1979)
10.7326/0003-4819-91-5-710
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
10.1016/S0002-9149(97)00075-1
Prognostic value of Doppler transmitral flow velocity patterns in acute myocardial infarction.
K. Sakata (1997)
10.1016/0002-8703(91)90771-9
Dependency of the pulsed Doppler-derived transmitral filling profile on the sampling site.
K. Miyaguchi (1991)
10.7326/0003-4819-88-2-168
Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization.
M. Bristow (1978)
10.1002/1097-0142(197307)32:1<9::AID-CNCR2820320102>3.0.CO;2-6
Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseases
C. Tan (1973)
10.1002/1097-0142(19800901)46:5<1109::AID-CNCR2820460506>3.0.CO;2-B
Anthracycline cardiotoxicity: Clinical and pathologic outcomes assessed by radionuclide ejection fraction
J. Ritchie (1980)
10.1200/JCO.1993.11.10.1906
Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer.
C. Schwartz (1993)
10.1016/0002-9149(91)90902-W
Effect of heart rate on left ventricular diastolic transmitral flow velocity patterns assessed by Doppler echocardiography in normal subjects.
M. Harrison (1991)
10.1002/1097-0142(19910715)68:2<435::AID-CNCR2820680237>3.0.CO;2-#
Exercise echocardiography in the detection of anthracycline cardiotoxicity
K. Weesner (1991)
10.1161/01.CIR.60.3.531
Cross‐sectional Echocardiography in Acute Myocardial Infarction: Detection and Localization of Regional Left Ventricular Asynergy
J. Heger (1979)
10.1002/1097-0142(197804)41:4<1265::AID-CNCR2820410408>3.0.CO;2-R
Echocardiography in adriamycin cardiotoxicity
K. R. Bloom (1978)



This paper is referenced by
Cardiotoxicity after Adjuvant Anthracycline-based Chemotherapy and Radiotherapy for Breast Cancer
T. Yau (2005)
10.18621/EURJ.410029
Cardioprotective effect of vitamin D and melatonin on doxorubicin-induced cardiotoxicity in rat model: an electrocardiographic, scintigraphic and biochemical study
S. Gül (2018)
10.1007/s12185-008-0112-5
Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation
S. Zver (2008)
10.1016/S0921-4410(03)21005-X
Topoisomerase II inhibitors.
K. Hande (2003)
10.1007/978-1-59745-306-6_19
Magnetic Resonance of Cardiomyopathies and Myocarditis
H. Abdel-Aty (2008)
10.5603/nmr-18727
Equilibrium radionuclide ventriculography in the assessment of cardiotoxicity of chemotherapy and chemoradiotherapy in patients with breast cancer.
G. Lapińska (2012)
10.7197/223.VI.531824
Protective effect of edaravone on adriamycin-induced cardiotoxicity in rats
H. Aygun (2019)
MANAGEMENT OF HAEMATOLOGICAL PATIENTS TREATED WITHCARDIOTOXIC DRUG
J. Dolenc (2008)
10.1016/B978-0-12-802509-3.00022-4
Nuclear Medicine Imaging and Cardiotoxicity
P. Erba (2017)
10.2478/raon-2013-0040
Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
T. Marinko (2014)
10.1007/s12350-015-0164-x
Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA)
E. J. Reuvekamp (2015)
10.1136/heartasia-2012-010117
Usefulness of myocardial performance index in multiple sclerosis mitoxantrone-induced cardiotoxicity
P. Pattoneri (2012)
10.1038/sj.bmt.1703890
Electrocardiogram is very useful for predicting acute heart failure following myeloablative chemotherapy with hematopoietic stem cell transplantation rescue
M. Akahori (2003)
10.1007/978-3-319-98184-0_5
Myocardial Dysfunction Associated with Cancer Therapy
M. Davis (2019)
10.1016/J.UCT.2006.04.001
Topoisomerase II inhibitors.
T. Toonen (2001)
Methoden und klinische Anwendung der Nuklearkardiologie: Positionsbericht
M. Schäfers (2002)
10.1016/S0002-9149(02)02312-3
Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone.
J. Strotmann (2002)
10.1093/ANNONC/MDF318
The clinical value of nuclear medicine in the assessment of irradiation-induced and anthracycline-associated cardiac damage.
I. Goethals (2002)
Cardiotoxicity after Adjuvant Anthracycline-based Chemotherapy and Radiotherapy for Breast Cancer
T. Yau (2005)
10.1053/J.SEMINONCOL.2004.08.006
Cardiac safety of liposomal anthracyclines.
M. Ewer (2004)
10.1002/cncr.11407
Congestive heart failure in patients treated with doxorubicin
S. Swain (2003)
10.3747/CO.2008.173
Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer
K. Towns (2008)
10.3990/1.9789036541947
Biomarkers for the early detection of cancer treatment induced cardiotoxicity
Bernard Frederik Bulten (2016)
10.1007/s10554-009-9518-2
Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer
J. M. Appel (2009)
10.1023/A:1024161024231
Mitochondrials complex I activity is reduced in latent adriamycin-induced cardiomyopathy of rat
K. Ohkura (2004)
10.1080/08880010500313603
EVALUATION OF ANTHRACYCLINE-INDUCED EARLY LEFT VENTRICULAR DYSFUNCTION IN CHILDREN WITH CANCER: A Comparative Study with Echocardiography and Multigated Radionuclide Angiography
F. Çorapçioğlu (2006)
10.1111/j.1540-8175.2008.00812.x
Assessment of Mitoxantrone‐Induced Cardiotoxicity in Patients with Multiple Sclerosis: A Tissue Doppler Echocardiographic Analysis
P. Pattoneri (2009)
10.1038/sj.bmt.1704763
Cardiac toxicity of high-dose chemotherapy
P. Morandi (2005)
10.1046/j.1328-8067.2001.01526.x
Longitudinal evaluation of anthracycline cardiotoxicity by signal‐averaged electrocardiography in children with cancer
D. Fukumi (2002)
10.1179/1607845413Y.0000000106
Acute physiological responses to physiotherapy applications pre and post autologous stem cell transplantation: an experimental study
I. Keser (2014)
10.1007/s11596-009-0326-7
Evaluation of epirubicin-induced cardiotoxicity by two-dimensional strain echocardiography in breast cancer patients
Xiaojun Bi (2009)
10.2169/INTERNALMEDICINE.43.379
QT dispersion correlates with systolic rather than diastolic parameters in patients receiving anthracycline treatment.
H. Nakamae (2004)
See more
Semantic Scholar Logo Some data provided by SemanticScholar